Phase 4
N=9
Growth Hormone and Endothelial Function in Children
Growth Hormone Deficiency · Panhypopituitarism · Short Stature
Bottom Line
View on ClinicalTrials.gov: NCT00373386 ↗Enrolled (actual)
9
Serious AEs
0.0%
Results posted
May 2018
Primary outcome: Primary: Reactive Hyperemic Response After 3 Months of Growth Hormone — 21.077 ml/dl min — p=0.644
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- growth hormone (Drug)
- Age
- Pediatric, Adult · 8+ yrs
- Sex
- All
- Sponsor
- Ohio State University
- Primary completion
- Jun 2007
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Reactive Hyperemic Response After 3 Months of Growth Hormone |
21.077 | 0.644 |
| SECONDARY Glucose |
87 | 0.018 sig |
| SECONDARY Insulin |
11.3 | 0.04 sig |
| SECONDARY HOMA |
43 | 0.004 sig |
| SECONDARY Triglycerides |
75 | 0.804 |
| SECONDARY LDL |
110 | 0.095 |
| SECONDARY HDL |
47 | 0.648 |
Summary
Objective: This study is designed to determine whether growth hormone treatment in children 8 to 18 years of age alters function of the lining of the arteries. This may play a role in increasing or decreasing the risk of heart disease.
Methods. Twenty children, for whom growth hormone therapy will be otherwise provided, will be studied before and 3 months after starting growth hormone. Subjects can be on other hormonal replacements but no other medications.
Each study will be done in the fasting state. The blood vessel function will be determined by measuring the change in forearm blood flow before and after blocking flow to the arm for 5 minutes. Blood will be drawn after the test to measure glucose, insulin and fats.
Eligibility Criteria
Inclusion Criteria
- isolated growth hormone deficiency (peak growth hormone level less than 10 ng/ml in response to arginine-insulin stimulation with cortisol responses and thyroid function tests), panhypopituitarism with appropriate thyroxine (normal free T4 level) and cortisol replacement (8-12 mg/m2/day) and non classic growth hormone deficiency (growth velocity less than 5 cm/year; peak growth hormone >10 ng/ml).
Exclusion Criteria
- Taking medications other than the appropriate hormonal replacement(L-thyroxine, cortisol, estrogen or testosterone, DDAVP)
Data sourced from ClinicalTrials.gov (NCT00373386). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.